Market Intelligence, Clinical Progress, and High-Purity Reagents for Estrogen Receptor Beta (ER-β) Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ESR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ESR2 (ER-beta) Recombinant Protein (LBD/Full-Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Sf9 Insect Cell / E. coli expressed. |
View ESR2 Products |
| Gene Delivery | ESR2 Promise-ORF / Lentivirus Full-length ORF for stable reporter cell lines and transcriptional assays. |
View ESR2 Products |
| Benchmark Ab | Anti-ESR2 Recombinant Antibody High-affinity positive control for immunohistochemistry and western blot validation. |
View ESR2 Products |
| Validator | ESR2 siRNA Set For target knockdown verification and specificity profiling. |
View ESR2 Products |
| Related Target A | ESR1 (Estrogen Receptor Alpha) Critical counter-screening target to ensure ESR2 subtype selectivity and prevent off-target estrogenic side effects. |
View ESR1 Products |
| Related Target B | AR (Androgen Receptor) Key nuclear receptor involved in cross-talk pathways in prostate and breast cancers. |
View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (ESR1 vs. ESR2) | Highly purified ESR1 and ESR2 ligand-binding domain (LBD) proteins verified by mass spectrometry for precise selectivity assays. |
| Conformation-sensitive ligand binding | Sf9 insect cell-expressed proteins preserving native post-translational modifications and folding. |
| Lack of clinical-grade positive controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| Off-target assay noise | Validated siRNA pooling systems included for strict target knockdown confirmation. |
Live ESR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of ESR2 (Estrogen Receptor Beta, ER-β) is undergoing a major clinical renaissance. Unlike ESR1 (ER-α), which behaves as a primary oncogene in breast cancer, ESR2 often functions as a tumor suppressor and a key modulator of immune and inflammatory microenvironments. The race for ESR2 therapeutics is intensifying, with major players shifting focus from non-selective estrogens to highly selective small-molecule agonists, selective estrogen receptor degraders (SERDs), and PROTACs designed to exploit its tissue-protective properties.
As first-generation selective agonists progress through clinical evaluations for oncology (such as prostate, ovarian, and triple-negative breast cancers) and inflammatory disorders, the next wave of R&D is targeting ESR2-mediated microenvironment modulation. Developing these therapies requires exceptional molecular selectivity to completely avoid ESR1-mediated feminizing and proliferative side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Agonists | Dialectic Therapeutics, Novartis | Solid Tumors, Autoimmune Diseases | Selectivity Assay (Requires highly pure ESR2 vs. ESR1 recombinant proteins) |
| PROTAC / Degraders | Arvinas, Accutar Biotechnology | Prostate & Breast Cancers | Degradation Kinetics (Requires Lentivirus-mediated stable reporter cell lines) |
| Targeted Monoclonal Antibodies | Academic Consortia, Biotech Startups | Immunotherapy, Diagnostics | Epitope Mapping (Requires sequence-verified native conformation proteins) |